U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Israel Defies Trump's Warning, Launches New Strikes on Iran Amid Growing Global Energy Crisis 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Japan Eyes Reduction in Inflation-Linked Bond Buybacks Amid Surging Investor Demand 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Oil Prices Hold Steady Amid Middle East Escalation and Sanctions Relief 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
